Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q4 Earnings
10:20am, Tuesday, 25'th Feb 2025
Evaluate the expected performance of Amneal (AMRX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?
10:15am, Tuesday, 25'th Feb 2025
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock
01:42pm, Monday, 24'th Feb 2025
J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company's generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfoli
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth
11:00am, Friday, 21'st Feb 2025
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Thursday, 06'th Feb 2025
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know
10:55am, Monday, 03'rd Feb 2025
The consensus price target hints at a 27.1% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
09:05am, Friday, 31'st Jan 2025
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
08:30am, Wednesday, 29'th Jan 2025
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025.
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
10:40am, Thursday, 16'th Jan 2025
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Amneal (AMRX) Upgraded to Strong Buy: Here's Why
01:00pm, Wednesday, 08'th Jan 2025
Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist.
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue?
10:15am, Tuesday, 12'th Nov 2024
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript
03:27pm, Friday, 08'th Nov 2024
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chie
Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
10:36am, Friday, 08'th Nov 2024
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compar
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates
08:10am, Friday, 08'th Nov 2024
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.19 per share a year ago.
